Back

Comparable exercise hemodynamic improvements with riociguat and selexipag under multimodal therapy including balloon pulmonary angioplasty in inoperable chronic thromboembolic pulmonary hypertension

31 August 2026 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Management of chronic thromboembolic pulmonary hypertension Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mrs Tomomi Sugiyama

Nagoya University, Nagoya (Japan)

6 More presentations in this session

Presentation thumbnail
Extended prospective follow-up of a randomised comparison of riociguat and selexipag under multimodal therapy in inoperable chronic thromboembolic pulmonary hypertension
Assistant Professor Y. Nakano (Nagoya, JP)
Abstract
Presentation thumbnail
Temporal evolution of multidisciplinary management for chronic thromboembolic pulmonary hypertension: a 30-year experience at a refererral center
Doctor M. Coronel (Corrientes, AR)
Abstract
Presentation thumbnail
Prediction of treatable occluded branches before balloon pulmonary angioplasty using CT imaging in patients with chronic thromboembolic pulmonary hypertension
Assistant Professor H. Hashimoto (Tokyo, JP)
Abstract
Presentation thumbnail
Cumulative institutional experience and the learning curve of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
Doctor R. Takano (Suita, JP)
Abstract
Presentation thumbnail
Progressive lesion-level hemodynamic improvement from immediate post-procedural assessment to follow-up after balloon pulmonary angioplasty
Assistant Professor Y. Nakano (Nagoya, JP)
Abstract

Access the full session

Session thumbnail
Management of chronic thromboembolic pulmonary hypertension

The Event

Event poster

ESC Congress 2026

31 August 2026 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy of pulmonary hypertension-targeted drugs for severe chronic thromboembolic pulmonary hypertension
3 September 2019
thumbnail
Congress Presentation
The hemodynamic effect of vericiguat during exercise right heart catheterization in patients with HFrEF
10 May 2026
thumbnail
Congress Presentation
Selexipag dosing and titration in the first 500 patients enrolled in SPHERE (SelexiPag: tHe UsErs dRug rEgistry)
2 September 2019
thumbnail
Congress Presentation
Different diagnostic criteria agreement for exercise pulmonary hypertension in chronic thromboembolic pulmonary disease
26 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources